BioSpace News Archive

Dantari, Inc., a clinical-stage biotechnology company developing best-in-class targeted therapeutics for the treatment of cancers and other diseases, announced its emergence from stealth mode with $47 million Series A financing.

Evogene Ltd. announced today that Bayer will pay Evogene an amount of $3.5 million under their joint seed traits collaboration agreement.

Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the launch of Ginkgo Enzyme Services.

Vevo Therapeutics, a biotechnology company using its Mosaic in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients, launched today with an oversubscribed and upsized $12M seed financing round.

REGENXBIO Inc. (Nasdaq: RGNX) today announced it has completed dosing in the expanded Cohort 2 of the Phase I/II trial of RGX-111 for the treatment of severe Mucopolysaccharidosis Type I (MPS I).

NextRNA Therapeutics today announced that Dominique Verhelle, Ph.D., Co-Founder, Chief Executive Officer and Chief Scientific Officer, will give a corporate presentation at the 5th Annual RNA-Targeted Drug Discovery Summit, which will be held December 13 – 15, 2022 in Boston.

Better Therapeutics, Inc. today announced positive topline results of the first-ever study evaluating the feasibility of using a prescription digital therapeutic to reduce liver fat and improve liver disease biomarkers in Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).

Actinium Pharmaceuticals, Inc. today announced that it has entered into a research collaboration with Columbia University to study Actimab-A, its clinical-stage CD33 targeting radiotherapeutic, with engineered hematopoietic stem cells (eHSCs) modified by CRISPR/Cas9 gene editing technology to knock out CD33 expression.

INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease will present data from UK patients with MDS or AML treated with INKmune™ at the annual American Society for Hematology (ASH) Conference held in New Orleans December 10th – 13th.

Eyenovia, Inc. today announced that Bren Kern, who currently serves as Eyenovia’s Senior Vice President of Manufacturing and Operations, has been promoted to Chief Operating Officer and Corporate Vice President, effective January 1st.